Protalix Biotherapeutics Inc (PLX) stock has fallen 22.11% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With PLX Stock Today?
Protalix Biotherapeutics Inc (PLX) stock is trading at $2.29 as of 11:07 AM on Thursday, Jun 3, a decline of -$0.18, or -7.29% from the previous closing price of $2.47. The stock has traded between $2.24 and $2.45 so far today. Volume today is low. So far 1,300,248 shares have traded compared to average volume of 2,097,459 shares.
To see the top 5 stocks in the Biotechnology industry click here.
More About Protalix Biotherapeutics Inc
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa, for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. Its pipeline products include Alidornase Alfa, Pegunigalsidase Alfa, and Oprx-106. The company's primary sources of revenues include its sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.
Click Here to get the full Stock Score Report on Protalix Biotherapeutics Inc (PLX) Stock.
